A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumours
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2018
Price : $35 *
At a glance
- Drugs Evofosfamide (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Molecular Templates; Threshold Pharmaceuticals
- 02 Aug 2017 According to Molecular Templates media release, Threshold Pharmaceuticals merged with Molecular Templates and the combined company is named as Molecular Templates.
- 01 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 07 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.